IL328245A - מפרק ליזוזומלי מבוסס cd25 ושימושים שלו - Google Patents
מפרק ליזוזומלי מבוסס cd25 ושימושים שלוInfo
- Publication number
- IL328245A IL328245A IL328245A IL32824526A IL328245A IL 328245 A IL328245 A IL 328245A IL 328245 A IL328245 A IL 328245A IL 32824526 A IL32824526 A IL 32824526A IL 328245 A IL328245 A IL 328245A
- Authority
- IL
- Israel
- Prior art keywords
- degrader
- lysosomal
- based lysosomal
- lysosomal degrader
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23306925 | 2023-11-08 | ||
| PCT/IB2024/061045 WO2025099632A1 (en) | 2023-11-08 | 2024-11-07 | Cd25 based lysosomal degrader and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL328245A true IL328245A (he) | 2026-07-01 |
Family
ID=89119323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL328245A IL328245A (he) | 2023-11-08 | 2024-11-07 | מפרק ליזוזומלי מבוסס cd25 ושימושים שלו |
Country Status (8)
| Country | Link |
|---|---|
| KR (1) | KR20260110182A (he) |
| CN (1) | CN122206696A (he) |
| AR (1) | AR134267A1 (he) |
| AU (1) | AU2024378103A1 (he) |
| IL (1) | IL328245A (he) |
| MX (1) | MX2026005608A (he) |
| TW (1) | TW202540169A (he) |
| WO (1) | WO2025099632A1 (he) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1027073A2 (en) | 1996-11-19 | 2000-08-16 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| ID26964A (id) | 1998-02-19 | 2001-02-22 | Xcyte Therapies Inc | Komposisi dan metode untuk pengaturan pengaktifan limfosit |
| GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
| EP1361892A4 (en) | 2001-01-17 | 2004-10-13 | Trubion Pharmaceuticals Inc | BINDING DOMAIN FUSION PROTEIN Immunoglobulin |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| AU2003295471B2 (en) * | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US9212226B2 (en) | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| LT3466972T (lt) | 2011-06-23 | 2026-06-25 | Ablynx Nv | Serumo albuminą surišantys baltymai |
| FI3366705T3 (fi) | 2012-09-12 | 2023-07-28 | Genzyme Corp | Muuttuneen glykosylaation ja vähentyneen efektoritoiminnan omaavia fc:n sisältäviä polypeptidejä |
| LT3248986T (lt) | 2014-05-16 | 2022-03-25 | Ablynx Nv | Imunoglobulino kintami domenai |
| US10227411B2 (en) * | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| HUE057241T2 (hu) | 2015-11-13 | 2022-04-28 | Ablynx Nv | Javított, szérumalbumint kötõ immunoglobulin variábilis domének |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| WO2018104444A1 (en) | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP3571224B1 (en) | 2017-01-17 | 2024-08-07 | Ablynx NV | Improved serum albumin binders |
| EP4442709A3 (en) | 2017-01-17 | 2024-12-25 | Ablynx NV | Improved serum albumin binders |
| JP7720785B2 (ja) | 2019-04-18 | 2025-08-08 | ブリストル－マイヤーズ スクイブ カンパニー | 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント |
| CN114466663B (zh) | 2019-07-25 | 2026-01-02 | 建新公司 | 以FcRn拮抗剂治疗抗体介导的障碍的方法 |
-
2024
- 2024-11-07 IL IL328245A patent/IL328245A/he unknown
- 2024-11-07 CN CN202480070513.1A patent/CN122206696A/zh active Pending
- 2024-11-07 KR KR1020267017755A patent/KR20260110182A/ko active Pending
- 2024-11-07 TW TW113142796A patent/TW202540169A/zh unknown
- 2024-11-07 WO PCT/IB2024/061045 patent/WO2025099632A1/en active Pending
- 2024-11-07 AU AU2024378103A patent/AU2024378103A1/en active Pending
- 2024-11-07 AR ARP240103052A patent/AR134267A1/es unknown
-
2026
- 2026-05-07 MX MX2026005608A patent/MX2026005608A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024378103A1 (en) | 2026-06-25 |
| WO2025099632A1 (en) | 2025-05-15 |
| MX2026005608A (es) | 2026-06-01 |
| CN122206696A (zh) | 2026-06-12 |
| TW202540169A (zh) | 2025-10-16 |
| AR134267A1 (es) | 2025-12-17 |
| KR20260110182A (ko) | 2026-07-14 |